One of the anti-inflammatory mechanisms of methotrexate (MTX), a common drug used in the treatment of RA, is to reduce the production of cytokines by upregulating the level of adenosine on neutrophils, especially the inhibition of TNF-α and IL-1β, which reduces the accumulation of white blood cells in the inflammatory site (51). Here, IL1B is linked to rheumatoid arthritis.